AUS
NZ
UK
CA
USA
IND
Highlights
- JP Morgan reiterates 'overweight' stance on Smith & Nephew, citing undervaluation and recovery potential.
- European medtech sector faces ongoing challenges, including slower market growth and geopolitical pressures.
- Smith & Nephew stands out for operational and market-driven improvement opportunities.
Smith & Nephew PLC (LSE:SN) has garnered continued support from JP Morgan analysts, who reaffirmed their 'overweight' stance on the medical device company. Analysts see the stock as undervalued and trading near trough levels, presenting opportunities for a significant re-rating as the company demonstrates recovery potential.
Sector Challenges Weigh on Performance
The broader European medtech sector has faced considerable challenges over the past four years, underperforming the wider market in three of those years. A modest late rally salvaged 2023, but lingering headwinds are expected to persist into the first half of 2025.
Key factors contributing to the sector’s difficulties include slower growth in dental and hearing markets, geopolitical uncertainty stemming from tariff threats, and China’s anti-corruption measures impacting operations. These challenges, combined with cautious outlooks from management teams, have tempered enthusiasm for the near-term prospects of medtech companies.
Smith & Nephew Positioned for Value
Amid these industry-wide pressures, Smith & Nephew is identified as a standout performer. Analysts at JP Morgan highlight the company’s potential for operational and market-driven improvements, positioning it for recovery despite the challenging environment.
JP Morgan’s strategy currently leans toward value-oriented stocks with scope for growth through strategic and operational initiatives. Smith & Nephew’s positioning aligns with this approach, making it a focal point for potential recovery in the medtech sector.
Peers Highlighted for Recovery Prospects
JP Morgan’s analysis also identified other companies with recovery potential. Fresenius SE was noted for ongoing operational gains, while Gerresheimer is emerging from a challenging year with conservative guidance for 2025. Alcon’s new product launches offer potential upside, though their impact is expected to be more prominent in the latter half of the year.
Market Reaction and Valuation
Smith & Nephew’s shares were trading within a range at 1,004p in late morning trading, with JP Morgan assigning a price target of 1,180p. The analyst sentiment reflects confidence in the company’s ability to navigate sector challenges and capitalize on opportunities for operational improvements.
Looking Ahead
As the European medtech sector continues to grapple with macroeconomic and geopolitical challenges, Smith & Nephew’s focus on recovery positions it as a notable player in the industry. With support from analysts and a strategic emphasis on operational gains, the company remains poised to unlock value as conditions improve.
